IL-23 inhibitor

New approvals and pipeline activity can expand future treatment options and affect availability, pricing, and research priorities for Crohn’s disease. Market analyses can signal which therapies companies expect to...

This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...

This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...

There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.

A new national approval means guselkumab (TREMFYA) may soon be an available treatment option for people with Crohn’s disease or ulcerative colitis in Egypt, potentially expanding choices for moderate-to-severe disease....

Long-term (five-year) data suggest guselkumab may provide sustained clinical and endoscopic benefit for people with moderate-to-severe Crohn’s disease, which is important for disease control and reducing need for...

Long-term data help patients and clinicians understand whether a biologic maintains benefit and safety over years. Sustained clinical remission and endoscopic healing are important outcomes linked to better long-term...

New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...

This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.

New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...

This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...

Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor.

A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...

TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming...

IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.

Based on the title and source metadata, this appears to be a market or business news related to Ulcerative colitis, Crohn's disease, and Guselkumab. The original article is from firstwordpharma.com.

This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

Cure8 found this source from wam.ae, but the page could not be read reliably yet. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor. Open the original article for the full details.

This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.

Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...

If approved, TREMFYA (guselkumab) could become an additional IL‑23 inhibitor option for adults with moderate‑to‑severe Crohn’s disease, including both IV and SC induction dosing. That may affect treatment choices for...

A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...

A CHMP positive opinion means guselkumab (Tremfya) could become an approved treatment option for adults with moderately to severely active Crohn’s disease in the EU, offering both IV and SC induction routes. This could...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from uk.finance.yahoo.com.

This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from specialtypharmacycontinuum.com.

If you have moderate to severe Crohn’s disease, this study suggests some patients who don’t respond to initial risankizumab induction may still benefit from a longer induction period, including improved symptoms and...

An FDA approval means guselkumab (Tremfya) is now an approved treatment option for adults with moderate-to-severe Crohn’s disease, including a unique option for fully subcutaneous induction. This may expand choices for...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor. Open the original article for the full details.

Cure8 found this source from wyomingnews.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.

This FDA approval adds another biologic option (an IL-23 inhibitor) for adults with moderate-to-severe Crohn’s disease, including both self-administered subcutaneous dosing and an IV induction route. New options may...

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

This is a new FDA approval of an IL-23 inhibitor (guselkumab) for adults with moderately to severely active Crohn disease, adding another biologic treatment option. It’s notable because guselkumab offers both IV and...

A newly FDA-approved option (Tremfya/guselkumab) may offer more flexible dosing that could affect how people with moderate-to-severe Crohn’s start biologic treatment.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...

Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Guselkumab.

An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did...

A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...

An FDA approval means a new biologic option (guselkumab/Tremfya) is available for adults with moderately to severely active Crohn’s disease and may change prescribing choices. The approval highlights a dosing flexibility...

A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...